AAV-mediated delivery of enzymes, neurotransmitter-modulating proteins, or neurotrophic factors has been extensively explored in Parkinson’s disease. While early studies suggested biological activity, several randomized controlled trials failed to meet primary clinical endpoints, highlighting the challenges of placebo effects, target engagement, and disease heterogeneity.
https://salienceclinical.com/

CNS disorders are now being reclassified by molecular signatures, circuit-level dysfunction, and digital phenotypes. This is not a technological upgrade; it is a strategic reset. Sponsors who continue to build programs around blunt diagnostic categories.
https://salienceclinical.com/

From Salience Clinical’s perspective, success over the next decade will depend on disciplined integration of advanced therapeutics with biomarker-guided precision medicine, early and sustained regulatory alignment, and realistic economic frameworks that balance innovation with healthcare system sustainability.
https://salienceclinical.com/

Medical-device development is unlike typical software or manufacturing environments because products directly impact patient safety and must satisfy stringent regulatory expectations across the entire product lifecycle.
https://salienceclinical.com/

Healthcare systems face a growing economic crisis: more than 13 million patients suffer from chronic wounds each year, yet traditional health-economic models capture only a fraction of the true burden.
https://www.linkedin.com/in/denis-k-medaffairs/